Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
Condition: Refractory Plasma Cell Myeloma Interventions: Drug: Dexamethasone; Biological: Elotuzumab; Drug: Pomalidomide Sponsors: Mayo Clinic; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials